Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.84 |
| ▸ | GAA | P10253 | 7/20 | 0.84 |
| ▸ | HPGD | P15428 | 7/20 | 0.84 |
| ▸ | GLA | P06280 | 6/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.84 |
| ▸ | CA9 | Q16790 | 5/20 | 0.84 |
| ▸ | CA12 | O43570 | 4/20 | 0.84 |
| ▸ | CA1 | P00915 | 4/20 | 0.84 |
| ▸ | CASP1 | P29466 | 3/20 | 0.84 |
| ▸ | CASP7 | P55210 | 3/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37677 | 0.92 | ALDH1A1 (1.00) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL29645144 | 0.92 | ALDH1A1 (1.00) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL28806970 | 0.92 | ALDH1A1 (1.00) | ALDH1A1KDM4EGAAHPGDGLA | |
| Hydrochloric Acid SCHEMBL2545954 | 0.90 | ALDH1A1 (0.96) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL1037558 | 0.90 | ALDH1A1 (0.96) | ALDH1A1KDM4EGAAHPGDGLA | |
| Bromide SCHEMBL18007249 | 0.90 | ALDH1A1 (0.96) | ALDH1A1KDM4EGAAHPGDGLA | |
| Hydrochloric Acid SCHEMBL567469 | 0.90 | ALDH1A1 (0.96) | ALDH1A1KDM4EGAAHPGDGLA | |
| Hydrochloric Acid SCHEMBL30762676 | 0.90 | ALDH1A1 (0.96) | ALDH1A1KDM4EGAAHPGDGLA | |
| Bromide SCHEMBL30457821 | 0.90 | ALDH1A1 (0.96) | ALDH1A1KDM4EGAAHPGDGLA | |
| Glycine SCHEMBL335759 | 0.90 | ALDH1A1 (0.77) | ALDH1A1KDM4EGAAHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114667145-A | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders | 拜尔哈文制药股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20170354744-A1 | METHOD OF SYNTHESIZING OF ANTIBODY CONJUGATES USING AFFINITY RESINS | ADC BIOTECHNOLOGY LTD. (GB) | 2017-12-14 | — | — | US | disclosed |
| EP-3223852-A1 | METHOD OF SYNTHESISING OF ANTIBODY CONJUGATES USING AFFINITY RESINS | Adc Biotechnology Ltd (GB) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016067016-A1 | METHOD OF SYNTHESISING OF ANTIBODY CONJUGATES USING AFFINITY RESINS | ADC BIOTECHNOLOGY LTD (GB) | 2016-05-06 | — | — | WO | disclosed |
| WO-2009075778-A2 | NONPEPTIDIC INHIBITORS OF CRUZAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-18 | — | — | WO | disclosed |
| US-6277984-B1 | USE AS FLUORESCENT MARKERS; FOR IMPARTING FLUORESCENCE TO BIOLOGICAL AND NONBIOLOGICAL MATERIALS TODETECT VARIOUS BIOLOGICAL OR OTHER MATERIALS BY PROCEDURES SUCH AS FLUORESCENCE MICROSCOPY | CARNEGIE MELLON UNIVERSITY | 2001-08-21 | — | — | US | disclosed |
| US-6207464-B1 | INCUBATING TARGET WITH DYE TO FORM A COVALENT BOND; BLUE FLUORESCING DYES | CARNEGIE MELLON UNIVERSITY | 2001-03-27 | — | — | US | disclosed |
| US-5986093-A | FLUORESCENT DYES | CARNEGIE MELLON UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
| US-5981747-A | FOR USE AS FLUORESCENT MARKERS | CARNEGIE MELLON UNIVERSITY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5852191-A | Rigidized monomethine cyanines | CARNEGIE MELLON UNIVERSITY (US) | 1998-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354744-A1 | METHOD OF SYNTHESIZING OF ANTIBODY CONJUGATES USING AFFINITY RESINS | FCGR1A, FCGR2A, FCGR3B | ALDH1A1 2199/4885KDM4E 2059/4885GAA 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.